Supplementary Information for Financial Results Q1 FY12/26

May 14, 2026

CHIOME

To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs

Chiome Bioscience Inc.

Agenda

1．Overview of Q1 FY12/26 “Financial results”

2．Overview of Q1 FY12/26 “Operation highlights”

Appendix.

Corporate information

Pipeline information

Overview of
Q1 FY12/26 “Financial results”

Financial results: Profit and Loss

(JPY in millions)

	Q1 FY2025	Q1 FY2026	Increase (decrease)	Main reasons for increase / decrease
Net sales	138	147	8	
Drug Discovery & Development	-	-	-	
Drug Discovery Support	138	147	8	
COS/SGA	403	379	(23)	
R&D Expense	203	174	(29)	Decrease in clinical development-related costs
Other costs	199	205	5	
Operating Loss	(264)	(232)	32	
Ordinary Loss	(265)	(232)	33	
Net Loss	(266)	(233)	32	

Financial results: Balance Sheet

(JPY in millions)

	As of Dec. 31, 2025	As of Mar. 31, 2026
Current assets	1,546	1,492
(Cash on hand in banks)	1,205	1,141
(Other current assets)	341	351
Non-current assets	180	177
Total assets	1,727	1,670
Current Liabilities	374	302
Non-current liabilities	230	55
Total liabilities	605	358
Total net assets	1,122	1,311
Total liabilities and net assets	1,727	1,670

Overview of
Q1 FY12/26 “Operation highlights”

Q1 FY12/26 Operation Highlights

Drug Discovery and Development – Pipeline

CBA-1205	✓ Patient enrollment for melanoma/hepatocellular carcinoma completed, evaluation of patients who continued treatment and data analysis ongoing ✓ Advancing pediatric cancer part, high frequency of DLK1 observed at present. ✓ Received a notice of allowance for a European patent for the CBA-1205 & lenvatinib.
CBA-1535	✓ Safety and tolerability evaluation in progress for patients with solid tumors, undergoing stepwise dose escalation. ✓ Protocol amended, following premedication such as steroid,further dose escalation is ongoing.

New technology development

DoppeLib™	✓ Collaboration with several companies underway, supported by innovative technology enabling high-throughput screening method of bispecific antibodies. Positioning this as a key technology for future IDD business to pursue new business opportunities.

IDD Business

Biosimilar businesses	✓ Discussions in progress with potential partners for new biosimilar development. ✓ Revenue from jointly developed biosimilars recorded as drug discovery support business.
Drug Discovery Platform	✓ Advancing clinical development consultation of drug discovery for biotech companies and scientific support for startups with Axcelead Drug Discovery Partners. ✓ Discussions commenced with potential partners aimed at securing new business opportunities, utilizing our research and drug discovery function, resulting in increasing scientific support with startup of biotech companies before and after founding.

Drug Discovery Support Business

Deals with pharmaceutical companies	✓ Net sales of ¥147 million in 20261Q. Increase 6.1% in revenue ✓ Leveraging a proprietary antibody platform to continue advancing antibody generation and related services.

Main Pipeline

★ First in class
★★ World first drug discovery modality moving into clinical phase

Code	Target	Therapeutic Area	Status
★ CBA-1205 (ADCC enhanced)	DLK1	Oncology	Phase 1 (jRCT2080225288) (NCT06636435)
★★ CBA-1535 (Tribody®)	5T4×CD3×5T4	Oncology	Phase 1 (jRCT2031210708) (NCT07016997)
★ PCDC (ADC)	CDCP1	Oncology/ADC	Non-clinical studies in progress
PTRY (Tribody®)	5T4×CD3×PD-L1	Oncology	Non-clinical studies in progress
PXLR	CXCL1/2/3/5	Oncology	Non-clinical studies in progress
PFKR	CX3CR1	Autoimmune disease	November 2024 Out-licensed to Asahi Kasei Therapeutics Corporation (formerly Asahi Kasei Pharma Corporation)

As of Mar. 31, 2026

For other pipeline projects, we continue to work towards achieving results and report progress as appropriate.

CBA-1205 Phase 1 Study

PR case confirmed with a hepatocellular carcinoma patient
Melanoma part was added



Study design and objectives	First part	Second part
	Target patients: patients with solid tumors ・Dose escalation starting with low dose ・Determine maximum safe dose ・Additional cohort with a higher dose than initially planned	Target patients: patients with hepatocellular carcinoma, melanoma, and pediatric cancer ・Confirm a suitable dose in the clinical study with hepatocellular carcinoma patients (optimal dose) ・Evaluate safety and initial efficacy signals

First part
- Demonstrated a favorable safety profile at doses up to 30mg/kg.
- **SD (stable disease) assesment has continued for more than 4 years, including tumor shrinkage** in a melanoma patient

Second part
- **Tumor shrinkage of more than 30% (PR)** has been observed in **a hepatocellular carcinoma patient** with confirmed expression of DLK1.
- Patient enrollment for **melanoma** and **hepatocellular carcinoma** completed, evaluations of patients who continued treatment and data analysis ongoing.
- Advancing **pediatric cancer** part based on joint research with IGTP in Europe and high frequency of DLK1 observed at present.

CBA-1535 Phase 1 Study

The first part of CBA-1535 Phase I study is in progress



Study design and objectives	First part (single agent)	Second part (combined use with cancer immunotherapy drugs)
	Target: Solid cancer patients • Starting to administer a low dose in increments to find the maximum dose that can be safely administered. • Evaluate initial drug efficacy signals	Target: Solid cancer patients • Administer the dose that was confirmed to be safe in the first part in increments. • Find the maximum dose that can be safely administered when combined with cancer immunotherapy drugs (IOs) • Evaluate early drug efficacy signals when combined

- The dosage is gradually increased. Beginning to see reactions in patients' blood, but there have been no safety concerns that would affect development so far.
- For possible out-licensing with only the data from the first part (single agent) study, we extended the first part to enhance the data.

Towards Future Out-licensing

CBA-1205: A program to maximize product value and out-licensing consideration

Hepatocellular carcinoma

+

Melanoma

Long SD in Phase I, 1st part

Pediatric solid tumors

Expanding clinical studies based on findings from the joint research.

=

Aimed at maximizing product value and improvement on economic terms in out-licensing

CBA-1535: A program aimed at out-licensing based solely on single agent data

Focusing clinical development for out-licensing with first part data, evaluation of safety and efficacy as a single agent.

⇒

Enhancing the likelihood of successful development for early-stage licensing to the companies with strong financial resources for development under this competitive T cell engager solid cancer area.

For the above clinical development programs, the aim is to acquire license agreements by obtaining data suggesting efficacy from ongoing Phase I studies.

Antibody Generaion Technology Platforms



For bispecific antibody discovery

Basic Concept of DoppeLib™

DoppeLib™ : High throughput screening technology bispecific antibody

Conventional method

mAb against antigen **A**

...200 clones

...200 clones

mAb against antigen **B**





Chiome's concept

mAb against antigen **A**

...200 clones

...200 clones

mAb against antigen **B**



Bulk vector preparation in a single tube

Easy

DoppeLib™



Secreted form

200 x 200 = **40,000 combinations**

Efficient



Vision of DoppeLib™



Parental-mAb generation or existing mAbs

DNA synthesis & pooled-plasmid prep.

DoppeLib™ High-throughput screening

Further optimization

Accelerating Research Cycle

By evaluating a vast number of parental monoclonal antibody combinations, we will unlock the potential of bi-specific antibodies.

Illustrations were created with BioRender.com.

IDD Business (Biosimilars)

Leveraging CMC function and its intelligence, engaged in biosimilar business which the Japanese government actively promotes to reduce healthcare costs.

Business Scope of Chiome



Cell line development

BUSINESS PARTNERSHIP

CHIOME Kidswell.Bio

Joint development of biosimilars

- Efficient use of management resources
- Sharing development costs
- Profit share

Clinical Development/Manufacturing and Marketing

Partner companies

Business Partnership Agreement with Alfresa Holdings in October, 2025.

Pursuing negotiation to increase the number of partnerships

Business Model of Biosimilar Development



CB: Chiome Bioscience

KWB: Kidswell Bio

*1 Milestone: Income received by the licensee at each milestone after out-licensing through the progress of clinical studies and others.

*2 Royalty: Income received as a percentage of the sales amount after a product is sold (launched)

IDD Development
Concept for Strengthening Consortium-based Startup Incubation



Engage with high-potential startups from the seed stage

Collaboration with venture capitals (VCs)/financial institutions

molecules/nucleic acids, etc.

antibodies

AXCELEAD Drug Discovery Partners

Busuiness alliance

CHIOME

Partner companies of Axcelead DDP

MYCENAX

our partner companies

Launch a new company as an option for incubated projects

Collaborating with government-approved VCs and overseas VCs

Our role: Provide bio discovery/CMC development capabilities from a manufacturing perspective

Drug Discovery Support Business

- Net sales of ¥147 million in 20261Q. Increase 6.1% in revenue
- Leveraging a proprietary antibody platform to continue advancing antibody generation and related services.



Major clients	Contract date
Chugai Pharmaceutical Co., Ltd.	Jun. 2011
Chugai Pharmabody Research Pte. Ltd	Aug. 2012
Mitsubishi Tanabe Pharma Co., Ltd.	Dec. 2016
Ono Pharmaceutical Co., Ltd.	Oct. 2018
Kyowa Kirin Co., Ltd.	Jul. 2019
Takeda Pharmaceutical Co., Ltd.	Feb. 2024
Sales collaboration	Contract date
Merck Ltd. (Japan)	Sep. 2024
FUJIFILM Wako Pure Chemical Corporation	Dec. 2024

Appendix. Corporate information

Corporate Overview

Biotech company dedicating to satisfy unmet medical needs



Mission

Shine light on unmet needs.
Bring a brighter future to patients.

Vision

Will become No. 1 biotech venture that discovers and develops antibody drugs for unmet medical needs

Management principle

- Place the highest priority on sound management and credibility and aim to become a corporation that grows with society.
- With creativity and science, develop therapeutic drugs for unmet medical needs, and contribute to the health of patients.
- Achieve successive product pipelines and improvement of corporate value through collaboration with external institutions.

■ Founded:
February 2005

■ Listed on the stock exchange:
Dec.2011
(Tokyo Stock Exchange Growth Section)

■ President and Chief Executive Officer:
Masamichi Koike, Ph.D.

■ Location :
<Head Office and Research Laboratories>
3-12-1Honmachi, Shibuya-ku, Tokyo
<Drug Discovery Laboratories>
2-13-3 Nogawahonchou, Miyamae-ku, Kawasaki-city, Kanagawa

■ Number of Employees :
64 (As of Mar. 31, 2026)

■ Business :
Chiome Bioscience (4583.T), is a public company leveraging a proprietary monoclonal antibody generating technology, for drug discovery and development, as well as providing drug discovery supports.

Business Segment

Drug Discovery and Development Business

This is business to obtain revenues such as upfront, milestone, and royalty payments relating to out-licensing of patents of pipeline product and drug candidates, and also, income from collaborative research.
It drives our future growth.

Drug Discovery Support Business

This is business to obtain revenues from antibody generation service by using platform technology that Chiome possesses to support drug discovery research at pharmaceutical companies, or for diagnostic and research purposes at academia or institutes on fee-for-service scheme.
It secures constant revenue stream.

Core Competencies that Support Our Business

Antibody drug discovery platform

Drug Discovery Research

Antibody Generation

Anitibody Functional Alteration
Affinity Maturation

Multivalent antibody generation

Protein preparation

Clinical development

Clinical Development PM capabilities
Clincal Studies Operations



Non-clinical studies

CMC development for Biologics
Manufacturing Drug Substance
Manufacturing Investigational Products

Patent strategy

Antibody drug development achievement

[Drug discovery Pipeline creation & out-licensing] [IND of clinical studies/Clinical development]
[Manufacturing drug substances/investigational products]

Our advantage

Discerning eye x operational capability (from research to clinical development in the fastest/most direct way) = Chiome's drug discovery capabilities

We operate an agile research and development structure, enabling effective investment decisions with minimal resources and labor costs, while pursuing maximum returns.

Core Technology for Antibody Generation

Antiobody generation technology

【ADLib® system】 Generate human antibodies in vitro without using living organism (animals)

- Obtain human-antibody in a short time
- Unlike animal based immunological method, immunology tolerance is not affected
- Utilizing automonous genetic diversification, it is possible to continue to producing high-affinity antibody maturation



ADLib®library

Multivalent antibody generation [technology to create lead antibodies through different combinations depending on various targets/binding methods

【Tribody®】 one molecule with three binding sites, enabling combining different functions

[Bispecific antibody generation technology(under the development)]

We are developing cell surface display technology for bispecific antibody generation that allows evaluating various samples in speedy manner applying ADLib® system

Technologythat enable to design antibodies which combine two different type targets freely.

Revenue model

Drug development flow vs our revenue models



License Type

Income from upfront payment of out-licensing drug candidates to pharmaceutical companies and collaborative research, milestone, royalty, etc.

Contract based model

Income from contracted R&D works, consulting services and others

Offering services to research institutions, pharmaceutical companies, etc.

	License model	Contract-based model
Drug Discovery Business	○	
Drug Discovery Support Business		○
IDD Business	○	○

General Image of Revenue in the Drug Discovery Business

As the stage progresses, the amount received in each milestone increases.
Royalties also to be generated at a fixed rate on sales following launch.



The above is the image of earnings to explain the Pharmaceutical Licensing Agreement. The actual agreements may vary in terms of the upfront payment, milestone stages and number/amounts of milestones, and royalty rate for each contract.

*1 Milestone: Income received by the licensee at each milestone after out-licensing through the progress of clinical studies and others.
*2 Royalty: Income received as a percentage of the sales amount after a product is sold (launched)

Growth Strategy

By integrating Human Resources, Materials, Money and Information across and beyond the company, sustainable growth is promoted by developing 3 distinct businesses through a 3-tier portfolio, enhancing corporate value



Significance of 3 Businesses

Drug Discovery Business: Research and development of drug discovery – source of growth –

Led by CBA-1205 and CBA-1535, aiming to secure out-licensing agreements for drug discovery pipeline. Through upfront payment upon concluding agreements that will contribute to a single year PL, as well as milestones/royalty that will contribute to future revenue base, the Company aims to acquire large revenue and enhance corporate value.

Drug Discovery Support Business: R&D support, second lab services – generating cash flow –

By offering antibody generation/antibody engineering and protein preparation, the Company aims to generate in short-term revenue through high value-added research services as a steady source of revenue

IDD: Drug Discovery platform business – expanding business opportunities –

By leveraging technical capabilities and drug discovery expertise, the Company supports biopharmaceutical discovery for pharmaceutical companies and drug discovery startups. Its scope covers exploratory research, clinical development and biosimilar development. Contract types range from service agreements to joint R&D, with flexible frameworks to advance projects and expand business opportunities.

Service based business contributes to financial stability, while joint R&D contributes to future revenue and corprate value.

Appendix. Pipeline information

Pipeline Development Strategy

- Leveraging our antibody discovery platform, generate therapeutic antibodies with Academia/drug discovery venture companies to own several drug discovery pipeline projects.
- For promising seeds, promote either out-licensing to pharma companies or establishing new companies for commercialization

Research/Development

Drug Discovery Research → **Antibody drug discovery platform** → **Clinical study**

Commercialization

Academia
Drug discovery venture companies
Pharmaceutical companies that do not have enough research to function for antibody drug discovery.

Chiome Bioscience
+
Partner companies

Research/Development (intermediary)

Promoting drug discovery research utilizing antibody drug discovery platform and/or IDD business

Pharmaceutical companies

CBA-1205 -In-House Program-

First in class

CBA-1205 (Humanized afucosylated anti-DLK1 antibody)	
Origin	A humanized antibody generated by hybridoma technology in Livtech which Chiome acquired in 2015.
ADCC	GlymaxX (ProBioGen)
Therapeutic Area	Liver cancer, lung cancer, neuroblastoma etc.
Expectation	First-in-class therapeutic antibody targeting intractable cancers. Providing new therapeutics for highly malignant tumors that are without effective therapeutic drugs including hepatocellular carcinoma.
Patent	Granted in Japan, US, Europe, China etc.

Phase I clinical study

First part: Evaluate the safety in patients with solid cancers.

- **No serious adverse reaction reported.**
- **SD (stable disease) evaluation with tumor shrinkage has been continued in a Melanoma patient and the continuous dosing period has exceeded more than 4 years. Dosing is still ongoing.**

Second part: Evaluate the safety and efficacy in patients with solid tumors.

- **One PR(Partial Response) case confirmed in a patient with hepatocellular carcinoma.**
- **Advancing the melanoma cohort part**
- **Pediatric cancer cohort added**

Unmet needs to be addressed

Providing new therapeutics for highly malignant tumors with no effective treatments available, including melanoma, pediatric cancer and hepatocellular carcinoma.

CBA-1205 First Part of Phase 1 Study (Safety)

No toxicity of Grade 3 or higher were observed
High level of safety was confirmed

CBA-1205 Related Adverse Events

Adverse Events (AE)	Dose (mg/kg)							Total (n=22)
	0.1 (n=3)	0.3 (n=3)	1 (n=3)	3 (n=4)	10 (n=3)	20 (n=3)	30 (n=3)	
Patients with CBA-1205 Related AEs	1	0	2	3	1	3	3	13
Grade 1-2	1	0	2	3	1	3	3	13
≧ Grade 3	0	0	0	0	0	0	0	0
Dose Limiting Toxicity	0	0	0	0	0	0	0	0
Serious Adverse Events	0	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0	0
Treatment Discontinuation	0	0	0	0	0	0	0	0

(As of Mar. 31, 2026)

Only Grade 1 (mild) or Grade 2 (moderate) study drug related adverse events were reported at each dose. No Grade 3 (severe or medically significant but not immediately life-threatening) or higher serious toxicity findings were reported. No adverse reactions that would have stopped dosing were reported, and the high safety of CBA-1205 was confirmed.

CBA-1535 -In-House Program-

CBA-1535（Humanized anti 5T4 & CD3 trispecific antibody)	
Origin	CBA-1535 is a T-cell engager, trispecific antibody, directed against the 5T4 tumor antigen, a protein found on various solid tumors and is thought to be involved in metastasis.
Therapeutic Area	Malignant mesothelioma, small cell lung cancer, non small cell lung cancer, TNBC etc.
Expectation	First-in-class therapeutic antibody with trispecific format Offer a new treatment option for a disease which has poor prognosis and where there are only a few effective treatments.
Patent	Granted in Japan, UK, US, EU China etc.

Phase I study: Dosing for patients has started in the first part for safety and initial drug efficacy evaluation.

Study sites: National Cancer Center Hospital

Shizuoka Cancer Center



CBA-1535

Unmet needs to be addresses

Providing new therapeutics for solid tumors with poor prognosis and limited effective treatment options, including malignant mesothelioma.

PCDC -Licensing-

First in class

PCDC（humanized anti-CDCP1 antibody for antibody drug conjugate）

Origin	Humanized anti-CDCP1 antibody discovered by Chiome's proprietary antibody technologies.
Therapeutic Area	Solid tumors (lung, colorectal, pancreatic, breast, ovarian etc.)
Expectation	CDCP1 is a First-in-class therapeutic target highly expressed in broad range of solid tumors, including standard-of-care resistant cases. High efficacy and safety expected from binding and toxicological profiles of the antibody.
Patent	Granted in Japan, China etc. Pending in US, Europe etc.

- Promoting out-licensing activities, mainly in the field of ADC
- Progressing in contacting out-licensing candidate companies in Japan and abroad at conferences.

Out-licensing strategy/target

As the development needs for combining the ADC technology and our antibodies are in higher demand in out-licensing candidate companies, we will prioritize our out-licensing activities with companies with ADC technologies who need antibodies for ADC.

Antibody-Drug Conjugate Technology



PTRY -Licensing-

PTRY（humanized antibody 5T4/CD3/PD-L1 multi-specific antibodies）
Target molecules：5T4×CD3×PD-L1

Origin	Therapeutic antibodies for cancer treatment using Tribody® technology consisting of three binding sites. Therapeutic antibodies for cancer treatment targeting antigen-binding sites 1) solid tumor expressing 5T4, 2) T-cell engager CD3, and 3) immune checkpoint inhibitor PD-L1.
Therapeutic Area	Malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, Triple Negative Breast Cancer (TNBC) etc.
Expectation	A new study drug for patients who have not responded adequately to standard cancer immunotherapy. It is also expected to be useful in contributing to the healthcare economy by reducing drug prices.
Patent	Patent application completed

CBA-1535
(5T4×5T4×CD3)



The binding site for PD-L1 is introduced

PTRY
(5T4×CD3×PD-L1)



The results of the joint research with Ceinge Biotecnologie Avanzate（“Ceinge”）in Italy were published in the Journal of Experimental & Clinical Cancer Research, and Cancers.

Passariello et al. (2022). Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. *Journal of experimental & clinical cancer research : CR, 41*(1), 269.

Manna et al. (2023). A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies. *Cancers, 15*(22), 5345

PXLR -Licensing-

PXLR (humanized anti-CXCL1/2/3/5 antibody) Target molecules: CXCL1/2/3/5	
Origin	Functional inhibitory antibody for CXCL1/2/3/5, chemoattractant of CXCR2 expressing cell. Cancer therapeutic antibody that improves drug-resistant cancer microenvironment
Therapeutic area	Solid tumors (gastric, breast, ovarian etc.)
Expectation	Cancer cells express CXCL1/2/3/5 and attract immunosuppressor cells that cause the drug-resistant environment. Dosing PXLR antibody will reduce immunosuppressor cells. It is expected to overcome drug-resistance and inhibit the recurrence of cancers.
Patent	Patent application completed.
Joint development partner(s)	Osaka Metropolitan University



CXCL1/2/3/5 is a ligand of CXCR2, G-protein-coupled receptor (GPCR), and is involved in various tumorigenesis and formation processes. Cancer cells attract immunosuppressive cells with CXCL1/2/3/5 and create a drug-resistant environment. PXLR weakens drug resistant ability of cancer cells by binding to CXCL1/2/3/5.

PFKR -Out-Licensed Products-

PFKR (humanized anti-CX3CR1 antibody) target molecules: CX3CR1	
Orgin	Functional inhibitory antibody of Fractalkine (CX3CL1) receptor and a therapeutic antibody that inhibits disease progression of autoimmune neurological diseases, etc.
Therapeutic area	Secondary Progressive Multiple Sclerosis (SPMS), neurodegenerative disorder etc.
Expectation	SPMS is an intractable form of multiple sclerosis and is a disease with a need to develop high safety and effective therapeutic agents. By suppressing cytotoxic Eomes-positive CD4+T cells function which are considered directly related to lesions in SPMS (demyelination, neurodegeneration), expected to inhibit the progression of symptoms.
Patent	Patent application completed
Joint development partner(s)	National Center of Neurology and Psychiatry



CX3CR1 is a type of G protein-coupled receptor(GPCR), and its ligand, Fractalkine (CX3CL1), causes the migration of CX3CR1-expressing cells to inflammatory sites.

In cytotoxic Eomes positive CD4+T cells, which are considered directly related to lesions in SPMS (demyelination, neurodegeneration), CX3CR1 is expressed in many.

PFKR: Exclusive License Agreement with Asahi Kasei Therapeutics Corporation

- Exclusive license agreement with Asahi Kasei Therapeutics Corporation (formerly Asahi Kasei Pharma Corporation) for our therapeutic antibody, —humanized anti-CX3CR1 antibody (project code: PFKR)—, on November 20, 2024
- Under the terms of the agreement, we grant Asahi Kasei Pharma worldwide license, with the right to grant sublicenses for the developement, manufacturing and commercialization of PFKR

PFKR

Exclusive developement, manufacturing and commercialization rights worldwide with sublicensing

→ AsahiKASEI THERAPEUTICS

Financial terms

- ◆ Upfront payment: ¥200 million
- ◆ Receive milestone payments based on future development and sales progress (up to ¥24.8 billion)

+

- ◆ After product launch

Royalties based on product net sales

Shine light on unmet needs.
Bring a brighter future to patients.

To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs

Disclaimer

- Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements.

- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.

- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.